PD59-05 COST EFFECTIVENESS OF ADJUVANT PEMBROLIZUMAB AFTER NEPHRECTOMY FOR RCC: INSIGHTS FOR PATIENT SELECTION FROM A MARKOV MODEL
暂无分享，去创建一个
R. Thompson | S. Boorjian | B. Leibovich | B. Costello | Vidit Sharma | K. Wymer | B. Borah | J. Moriarty | Daniel D. Joyce